Biolase
BIOL
BIOL was delisted on the 18th of June, 2024.
28 hedge funds and large institutions have $17.8M invested in Biolase in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
7% more capital inflows, than outflows
Capital inflows: $2.7M | Capital outflows: $2.53M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.93% less ownership
Funds ownership: 41.77% → 38.84% (-2.9%)
13% less funds holding
Funds holding: 32 → 28 (-4)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Oracle Investment Management
Greenwich,
Connecticut
|
+$2.55M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$34.5K |
| 3 |
Virtu Financial
New York
|
+$34.5K |
| 4 |
Two Sigma Securities
New York
|
+$25.9K |
| 5 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
+$17.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
-$1.12M |
| 2 |
Granite Investment Partners
El Segundo,
California
|
-$924K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$155K |
| 4 |
D.E. Shaw & Co
New York
|
-$139K |
| 5 |
PCMI
Princeton Capital Management Inc
Princeton,
New Jersey
|
-$68.9K |
BIOL Hedge Fund Activity: Q3 2017 in Review
28 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Biolase (BIOL) for Q3 2017, worth a combined $17.8M — down 35% from $27.5M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BIOL and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Oracle Investment Management, adding an estimated $2.55M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $1.12M sold.
- 28 institutional investors held Biolase (BIOL) as of Q3 2017, down from 32 in Q2 2017.
- Funds reported $17.8M of Biolase stock for Q3 2017, down 35% quarter-over-quarter.
- 3 funds opened new Biolase positions in Q3 2017 and 6 closed out, a net change of -3 holders.
- The largest Biolase buyer in Q3 2017 was Oracle Investment Management, an estimated $2.55M added.
- The largest Biolase seller in Q3 2017 was Consonance Capital Management, an estimated $1.12M sold.
Based on aggregated 13F filings for Q3 2017.